Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management

6Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Transdermal buprenorphine (TDB) has demonstrated effectiveness in treating a range of chronic pain conditions, including cancer pain, nociceptive pain, and neuropathic pain and has a favorable safety profile. Worldwide, clinical experience of its use is relatively limited. There is considerable misunderstanding about the pharmacology, mechanism of action, and safety of buprenorphine. There is also limited guidance on the appropriate use of TDB for chronic pain management. This article presents an overview of TDB and also provides practical recommendations for its use as part of a multifaceted strategy in chronic cancer and non-cancer pain.

Cite

CITATION STYLE

APA

O’Brien, T., Ahn, J. S., Chye, R., Le, B., Lu, H., Olarte, G., … Hadjiat, Y. (2019). Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management. Journal of Opioid Management, 15(2), 147–158. https://doi.org/10.5055/jom.2019.0496

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free